StocksFin Logo
Evotec SE country of incorporation
|
|
4,715 employees
NASDAQ | Healthcare | Drug Manufacturers—Specialty & Generic
Premier, Inc. country of incorporation
|
|
Ms. Susan DeVore
|
2,600 employees
NASDAQ | Healthcare | Health Information Services
Q322 reported Sep 30, 2022 Reporting Period
$173.88M 8.9% vs. Q321 Revenues Q322
16.34% -39.5% vs. Q321 Gross Profit Margin
-27.19% ! -132.3% vs. Q321 Net Profit Margin
-79.81M ! -483.8% vs. Q321 Free Cash Flow Q322
$-0.14 ! -132.9% vs. Q321 EPS Q322
Period
Profitable?
Revenue Growth?
Net Profit Growth?
FCF Growth?
OCF Growth?
EPS Growth?
Pays Dividend?
Q322
Q123
0.6%
Q123 reported Nov 1, 2022 Reporting Period
$313.87M -14% vs. Q122 Revenues Q123
64.35% 10.9% vs. Q122 Gross Profit Margin
13.61% -59.3% vs. Q122 Net Profit Margin
55.82M 1.1% vs. Q122 Free Cash Flow Q123
$0.36 -63.6% vs. Q122 EPS Q123
-
Period
Profitable?
Revenue Growth?
Net Profit Growth?
FCF Growth?
OCF Growth?
EPS Growth?
Pays Dividend?
Q322
Q123
0.6%
Loading...
Loading...
Ratios
As of
Dec 31, 2022
Dec 31, 2022
Quick Ratio
2.92
0.23
Current Ratio
3.18
0.72
Cash Ratio
1.23
0.1
Price to Book
2.25
1.8
Price to Sales
3.55
11.55
Price to Earnings
-15.19
16.22